Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) has been associated with metabolic disturbances characterized by downregulation of AMP-activated protein kinase (AMPK), a critical sensor of the cellular energy status. Therapeutic activation of AMPK by metformin could inhibit cyst enlargement by inhibition of both the mammalian target of rapamycin pathway and fluid secretion via the CFTR chloride channel.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2020
- Source ID
- 10.34067/kid.0004002020
Entities
People
- Andrew D. Althouse
- Dana C. Miskulin
- Kaleab Z. Abebe
- Kenneth R. Hallows
- Kyongtae T. Bae
- Ronald D. Perrone
- Stephen Seliger
- Terry Watnick
Organizations
- National Center for Advancing Translational Sciences
- National Institutes of Health
- Tufts Medical Center
- United States Department of Defense
- University of Maryland School of Medicine
- University of Pittsburgh School of Medicine
- University of Southern California